Notice of Results & Investor Presentation
20/04/2022 09:05
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220420:nRST7321Ia&default-theme=true
RNS Number : 7321I Instem plc 20 April 2022
Instem plc
("Instem" or the "Company")
Notice of Results
Instem plc (AIM: INS), a leading provider of IT solutions to the global life
sciences market, will announce results for the year ended 31 December 2021 on
Tuesday 26 April 2022.
Analyst Presentation: 09.30, Tuesday 26 April
Management will be hosting a presentation via web conference on the day of the
results at 09.30. Analysts wishing to join should register their interest by
emailing instem@walbrookpr.com (mailto:instem@walbrookpr.com) or by
telephoning 020 7933 8780.
Investor Presentation: 16:00, Tuesday 26 April
Management will be providing a presentation and hosting an Investor Q&A
session on the results and future prospects at 16:00 on the day, through the
digital platform Investor Meet Company. Investors can sign up for free and add
to attend the presentation via the following link
https://www.investormeetcompany.com/instem-plc/register-investor
(https://www.investormeetcompany.com/instem-plc/register-investor)
Questions can be submitted pre-event via your Investor Meet Company dashboard
up until 9am the day before the meeting or at any time during the live
presentation.
For further information, please contact:
Instem plc Via Walbrook
Phil Reason, CEO
Nigel Goldsmith, CFO
Singer Capital Markets (Nominated Adviser & Broker) +44 (0) 20 7496 3000
Peter Steel
Alex Bond
Rachel Hayes
Stifel Nicolaus Europe Limited (Joint Broker) +44 (0) 20 7710 7600
Ben Maddison
Alex Price
Walbrook Financial PR +44 (0) 20 7933 8780
Tom Cooper instem@walbrookpr.com
Nick Rome
About Instem
Instem is a leading provider of IT solutions & services to the life
sciences market delivering compelling solutions for Study Management,
Regulatory Submissions, Clinical Trial Acceleration, and Informatics-based
Insight Generation.
Instem solutions are in use by over 700 customers worldwide, including all of
the largest 25 pharmaceutical companies, enabling clients to bring life
enhancing products to market faster. Instem's portfolio of software solutions
increases client productivity by automating study-related processes while
offering the unique ability to generate new knowledge through the extraction
and harmonisation of actionable scientific information.
Instem products and services address aspects of the entire drug development
value chain, from discovery through to market launch. Management estimate that
over 50% of all drugs on the market have been through some part of Instem's
platform during their development.
To learn more about Instem solutions and its mission, please
visit www.instem.com (http://www.instem.com/)
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END NORURRWRUSUSURR